Indication

For the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.

Medicine details

Medicine name:
naldemedine (Rizmoic)
Pharmaceutical company
Shionogi Limited
BNF chapter
Gastro-intestinal system
Submission type
Full
Status
Publication due date:
13 April 2020
SMC meeting date:
03 March 2020
Patient group submission deadline:
03 February 2020